Novacea Contacts: Schering-Plough Contacts: Media: Paul Laland Mary-Frances FarajiDevelopment and Commercialization Agreement • May 30th, 2007 • Novacea Inc • Pharmaceutical preparations
SOUTH SAN FRANCISCO, CA and KENILWORTH, NJ — May 30, 2007—Novacea, Inc. (NASDAQ: NOVC) and Schering-Plough Corporation (NYSE: SGP) today announced that they have entered into an exclusive worldwide license agreement for the development and commercialization of Asentar™ (DN-101). Novacea is currently conducting a large international Phase 3 trial (ASCENT-2) evaluating Asentar in 900 patients with androgen-independent prostate cancer (AIPC). Asentar is a novel, proprietary, high-dose oral formulation of calcitriol, a potent hormone that exerts its effects through the vitamin D receptor (VDR).
